Background: Rezafungin is a novel echinocandin with excellent activity against common Candida species; however, limited data are available regarding rare Candida species.
Introduction
Rezafungin is a novel, once-weekly echinocandin in development for treatment of candidaemia and invasive candidiasis, with a Phase 3 trial currently under way, and for prophylaxis against invasive fungal infections caused by Candida, Aspergillus and Pneumocystis spp. in patients undergoing blood or marrow transplantation. 1, 2 Rezafungin has excellent in vitro activity, comparable to that of other echinocandins, against the five most frequently isolated Candida species (Candida albicans, Candida glabrata, Candida tropicalis, Candida parapsilosis sensu stricto and Candida krusei) using either CLSI or EUCAST broth microdilution (BMD) methodologies. [3] [4] [5] However, limited data are available regarding activity against less common Candida species. Therefore, our study aimed at determining the in vitro susceptibility of 668 clinical isolates of 5 common and 19 rare Candida species, as well as 21 clinical isolates of Saccharomyces cerevisiae. The activity of rezafungin was compared with that of five licensed systemic antifungal agents (anidulafungin, caspofungin, micafungin, fluconazole and amphotericin B).
Materials and methods

Isolates
The vast majority of 689 non-duplicate clinical isolates were collected between January 2005 and December 2018 in our diagnostic laboratory. All C. albicans, C. glabrata, C. tropicalis, C. parapsilosis sensu stricto, C. krusei, Candida rugosa, Candida catenulata, Lodderomyces elongisporus and S. cerevisiae isolates were derived from normally sterile body sites (blood, cerebrospinal, pleural and peritoneal fluids, deep wounds, etc.). At least one-third of the isolates were cultured from normally sterile body sites in the case of the other Candida species as well. In addition, 14 ATCC and type strains were also tested ( Table 1) . Clinical isolates were obtained prior to antifungal administration and identified with MALDI Biotyper (Bruker, Bremen, Germany) and/or PCR ribotyping. [6] [7] [8] [9] Antifungal susceptibility testing All isolates were tested by BMD according to CLSI in RPMI-1640 (Sigma, Budapest, Hungary). 10 MIC assays were conducted in U-bottom, tissue culture-treated microtitre test plates (TPP Techno Plastic Products AG, Switzerland; cat. no. 92097). Rezafungin pure powder was provided by Cidara Therapeutics, Inc. (San Diego, CA, USA). Caspofungin, micafungin and anidulafungin were obtained from Molcan Corporation (Richmond Hill, Ontario, Canada). Amphotericin B and fluconazole were purchased from Sigma (Budapest, Hungary). The concentration ranges tested were 0.004-2 mg/L for rezafungin, anidulafungin, caspofungin and micafungin, 0.015-8 mg/L for amphotericin B and 0.06-32 mg/L for fluconazole. In cases of the 'psilosis' group and Candida guilliermondii, the ranges for all four echinocandins were 0.015-8 mg/L. Neither a clinical breakpoint nor an epidemiological cut-off value (ECV) has been published for rezafungin against Candida species. The revised species-specific CLSI clinical breakpoints were used in cases of C. albicans, C. glabrata, C. parapsilosis sensu stricto, C. tropicalis, C. krusei and C. guilliermondii for anidulafungin, caspofungin, micafungin and fluconazole (except C. guilliermondii for fluconazole, where an ECV of 8 mg/L was used). 11, 12 The previously established ECVs were used for anidulafungin, caspofungin, micafungin and fluconazole for Candida kefyr, Candida lusitaniae, Candida dubliniensis and Candida orthopsilosis. [12] [13] [14] For amphotericin B, an ECV of 2 mg/L was used for the previously mentioned Candida species. 12, 13 In the case of Candida auris for anidulafungin, caspofungin, micafungin, amphotericin B and fluconazole, we used the tentative MIC breakpoints as suggested by the CDC. 15 For other Candida species and S. cerevisiae neither clinical breakpoints nor ECVs exist, thus only MIC 50/90 values are shown.
Quality control strains C. krusei ATCC 6258 and C. parapsilosis ATCC 22019 were included on each day of testing (25 different days).
Results
MIC values for the 14 ATCC and type strains are shown in Table 1 . MIC values of the six antifungal agents for the quality control strains were always within the accepted ranges. 10, 11 MIC values of rezafungin also fell always within the 24 h quality control ranges tentatively accepted by CLSI (January 2018 Subcommittee on Antifungal Susceptibility Tests meeting; C. krusei ATCC 6258, 0.015-0.12 mg/L; C. parapsilosis ATCC 22019, 0.25-1 mg/L).
Activity of echinocandins against Candida species and S. cerevisiae isolates
Rezafungin inhibited all C. albicans isolates at 0.12 mg/L, similarly to anidulafungin and micafungin, but only 70.4% were susceptible to caspofungin (Table 2) . Susceptibility patterns were similar to the closely related C. dubliniensis and Candida africana isolates, as well as to C. tropicalis ( Table 2) .
Activity of rezafungin (MIC 50/90 , 0.06/0.12 mg/L) against C. glabrata was comparable to that of anidulafungin and micafungin. Susceptibility rates were 100%, 100% and 4.9% for anidulafungin, micafungin and caspofungin, respectively ( Table 2) .
All four echinocandins showed similar activities against the 'psilosis' group and C. guilliermondii; the most susceptible was Candida metapsilosis (MIC 90 was 0.5 mg/L) ( Table 2 ). In the case of 53.3% of C. orthopsilosis isolates, MICs were higher than the ECV (0.5 mg/L) for caspofungin (Table 2) .
C. krusei isolates were inhibited by 0.12 mg/L rezafungin. All isolates were susceptible to anidulafungin and micafungin, but only 11.3% were susceptible to caspofungin (Table 2) . Rezafungin, anidulafungin and micafungin, but not caspofungin, were highly active against the other fluconazole-resistant Candida species, Candida inconspicua (Table 2) .
Rezafungin MIC 50/90 values were 0.06/0.12 and 0.12/0.25 mg/L for C. kefyr and C. lusitaniae, respectively. Against these two species, anidulafungin was the most active. In the case of C. kefyr, Tóth et al. 
Discussion
Results of this study, consistent with other published data, demonstrate that rezafungin MIC values for the five most common Candida species, including fluconazole-resistant isolates, were comparable to those of anidulafungin and micafungin. 2-5 Activity of rezafungin was comparable to anidulafungin and micafungin against C. kefyr, C. lusitaniae and C. dubliniensis, as well as against the emerging fluconazole-resistant C. auris and C. inconspicua. As expected, against C. guilliermondii, C. orthopsilosis, C. metapsilosis and C. carpophila all echinocandins including rezafungin showed higher MIC values, similarly to C. parapsilosis sensu stricto. 16 Rezafungin at 0.12 mg/L was active against very rare Candida species (C. lipolytica, C. fabianii, C. sojae, C. pulcherrima, C. pararugosa and C. rugosa) and showed activity against S. cerevisiae comparable to anidulafungin or micafungin. C. sojae has not been isolated from clinical specimens previously; our 10 isolates, including 1 bloodstream isolate, draw attention to this primarily plant pathogen frequently misidentified as Candida sake using traditional identification methods. 9 Although rezafungin MIC values were similar to those of micafungin and of anidulafungin, as might be expected given the latter's structural similarities to rezafungin, 17 MIC values of caspofungin were markedly higher for almost all Candida species studied. Our caspofungin MIC distributions were in line with the previously well-documented limitation that caspofungin susceptibility testing suffers from significant interlaboratory variability and is therefore not recommended. 18 As all three echinocandin comparators (anidulafungin, caspofungin and micafungin) originated from the same supplier, drug source does not explain this difference in antifungal efficacy. However, the quality of the microtitre plate (treated versus untreated polystyrene trays) may have influenced differentially our MIC values obtained with the different echinocandins, as previously demonstrated by Fothergill et al. 19 This may also be a factor in MIC differences found between Rezafungin activity against rare Candida species JAC laboratories testing rezafungin susceptibility. 5 Although our MIC data derived from a single centre and we used tissue culturetreated microtitre test plates from the same batch, their impact on rezafungin MIC distribution could not be entirely ruled out. We have provided a 'head-to-head' comparison between the three clinically available echinocandins and rezafungin using CLSI reference BMD methodology. Although the vast majority of clinical strains were isolated from a single centre, our anidulafungin, micafungin, fluconazole and amphotericin B MIC data for the tested Candida species were comparable to data reported by others. 20 The investigational echinocandin rezafungin showed excellent in vitro activity against Candida species, including the emerging potentially MDR C. auris, as well as against S. cerevisiae. Rezafungin had similar activity to other echinocandins (excluding caspofungin) against common and, notably, against clinically relevant uncommon Candida species.
